<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807543</url>
  </required_header>
  <id_info>
    <org_study_id>ppprom</org_study_id>
    <nct_id>NCT04807543</nct_id>
  </id_info>
  <brief_title>Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes</brief_title>
  <official_title>Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of 17-hydroxyprogesterone caproate (17P)&#xD;
      therapy on the latency period in pregnant women with Preterm premature rupture of membranes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After taking informed written consent, the recruited patients will be subjected to the&#xD;
      following:&#xD;
&#xD;
        1. Detailed history&#xD;
&#xD;
             -  Personal History: Name, age ,residence ,special habits of medical importance&#xD;
&#xD;
             -  Obstetric history: first day of last menstrual period for accurate estimation of&#xD;
                gestational age and antenatal care&#xD;
&#xD;
             -  Past history: history of any medical disorder or surgical history with particular&#xD;
                emphasis on prior PPROM or preterm labor&#xD;
&#xD;
             -  History of the present pregnancy: Medical or surgical condition to define high risk&#xD;
                pregnancy.&#xD;
&#xD;
        2. Examination of the patients General examination: blood pressure, pulse, temperature&#xD;
&#xD;
           Abdominal examination:&#xD;
&#xD;
             -  Inspection: fundal level, scars, umbilicus.&#xD;
&#xD;
             -  Palpation: presence of contractions, fetal lie and presentation.&#xD;
&#xD;
             -  Pelvic Examination only by sterile speculum to exclude cord prolapse , bloody&#xD;
                liquor and cervical dilatation and effacement&#xD;
&#xD;
             -  Non stress test to ensure reassuring fetal well being&#xD;
&#xD;
             -  Ultrasound examination to:-&#xD;
&#xD;
                  -  Assess fetal viability.&#xD;
&#xD;
                  -  Amniotic fluid index.&#xD;
&#xD;
                  -  Determine gestational age.&#xD;
&#xD;
                  -  Exclude major anomalies.&#xD;
&#xD;
                  -  Placental location.&#xD;
&#xD;
        3. Baseline laboratory investigations:&#xD;
&#xD;
             -  Complete blood count (CBC).&#xD;
&#xD;
             -  Prothrombin time (PT).&#xD;
&#xD;
             -  Activated partial thromboplastin time (aPTT).&#xD;
&#xD;
             -  Liver and kidney function.&#xD;
&#xD;
      The included patients were randomized using sealed opaque envelope method into one of two&#xD;
      groups:&#xD;
&#xD;
      Group I (study group): in which 17-hydroxyprogesterone caproate (17P) (250 mg in castor oil,&#xD;
      1 mL total volume, intramuscular injection weekly) will be administered.&#xD;
&#xD;
      Group II (control group): in which an identical-appearing placebo (1 mL castor oil only) will&#xD;
      be administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prolongation of the pregnancy until a favorable gestational age</measure>
    <time_frame>10 to 12 weeks (up to 34.0 weeks of gestation or documentation of fetal lung maturity at 32.0 to 33.9 weeks.)</time_frame>
    <description>The most common method of measuring gestational age in weeks is by calculating the time since the last menstrual period based on dates provided by a woman at the first prenatal visit IF not available first trimester Ultrasound will be used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency .</measure>
    <time_frame>10 to 12 weeks (interval in weeks from randomization to delivery)</time_frame>
    <description>The most common method of measuring gestational age in weeks is by calculating the time since the last menstrual period based on dates provided by a woman at the first prenatal visit IF not available first trimester Ultrasound will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>1 week (from delivery to 1 week post Natal)</time_frame>
    <description>by Apgar score ,blood gases ,and labs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Preterm Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>castor oil, 1 mL total volume intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-hydroxyprogesterone caproate</intervention_name>
    <description>intramuscular injection weekly</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Castor Oil</intervention_name>
    <description>intramuscular injection weekly</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age between 24 and 34 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or obstetric conditions that could put them at risk for uterine atony ,&#xD;
             postpartum hemorrhage AND infection, such as&#xD;
&#xD;
               -  Emergency Cesarean section.&#xD;
&#xD;
               -  Chorioamnionitis.&#xD;
&#xD;
               -  Placenta previa.&#xD;
&#xD;
               -  Multiple gestation.&#xD;
&#xD;
               -  Preeclampsia.&#xD;
&#xD;
               -  Macrosomia.&#xD;
&#xD;
          -  Non reassuring fetal status or fetal distress&#xD;
&#xD;
          -  Presence of fetal anomalies incompatable with life&#xD;
&#xD;
          -  Woman with antepartum haemorrhage&#xD;
&#xD;
          -  Diagnosis of Established preterm labor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain shams university</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Castor Oil</mesh_term>
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

